Delivery Order 36F79721D0068-36C26123N0657
Award Date 6/9/23
Potential Completion Date 8/9/23
Potential Value $195K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Princeton, NJ, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm-fixed-price delivery order to Urogen Pharma Inc., a for-profit pharmaceutical company, to provide JELMYTO kits. The $98,856.06 order is part of the VA's Pharmaceuticals and Drugs Federal Supply Schedule contract and will be fulfilled by May 10, 2024. Urogen Pharma holds several other VA contract vehicles for JELMYTO, a drug used to treat low-grade upper tract urothelial cancer in veterans, including multiple...
- The Department of Veterans Affairs (VA) awarded a firm-fixed-price delivery order to Urogen Pharma Inc., a for-profit pharmaceutical company, to provide the drug JELMYTO. The order, valued at $98,856.06, is being placed under the VA's Pharmaceuticals and Drugs Federal Supply Schedule contract. JELMYTO is used to treat low-grade upper tract urothelial cancer in veterans. This order is one of several federal contracts Urogen Pharma holds with the VA to supply JELMYTO, including a $2.5 million...
- This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to UroGen Pharma Inc., a for-profit pharmaceutical company, for the supply of JELMYTO kits. The contract has a ceiling value of $102,264.12 and is valid through September 30, 2025. The contract was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is structured as a firm fixed-price delivery order. No set-aside was used. UroGen Pharma has held multiple indefinite delivery vehicle...
- The Department of Veterans Affairs Veterans Health Administration awarded a $97,430 firm fixed price delivery order against GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB) to Urogen Pharma Inc. to provide JELMYTO, a treatment for low-grade upper tract urothelial cancer. The contract has a period of performance of June 22, 2023 through June 23, 2023 and will be performed in La Vergne, Tennessee. GSA Schedule FSS-61-IB, administered by the VA-VHA, provides pharmaceuticals and drugs to support...
- The Department of Veterans Affairs, through Veterans Integrated Service Network 5 (VISN 5), awarded a $10,303.55 delivery order to Otsuka America Pharmaceutical Inc. for Jynarque 45mg on February 5, 2021, with an ultimate completion date of February 10, 2021. This firm-fixed price delivery order, issued without a set-aside designation, was performed at the contractor's location in Riverwoods, Illinois. Jynarque (tolvaptan) is a specialty pharmaceutical used to treat autosomal dominant polycystic...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order valued at $37,742.16 to Otsuka America Pharmaceutical Inc. on June 25, 2024, with an ultimate completion date of August 26, 2024. This firm-fixed price delivery order procures Jynarque (tolvaptan), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. The award was issued under the Pharmaceuticals and Drugs...
- The Department of Veterans Affairs' Veterans Integrated Service Network 6 awarded a $11,413.72 delivery order to Otsuka America Pharmaceutical Inc. on May 17, 2022, for the supply of medication to be delivered to Potomac, Maryland. This firm fixed-price delivery order, with an ultimate completion date of May 31, 2022, contains no set-aside designation and represents a direct procurement under the company's existing Blanket Purchase Agreement for pharmaceutical products. The award falls under the...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order to Otsuka America Pharmaceutical Inc. for Jynarque (tolvaptan) on September 26, 2023, with a ceiling value of $12,224.60. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2023, was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and did not utilize a set-aside designation. The product will be delivered to...
- The Department of Veterans Affairs, Veterans Integrated Service Network 22 (VISN 22) awarded a delivery order to Otsuka America Pharmaceutical Inc. for Tolvaptan (Jynarque) on November 18, 2020, with a ceiling value of approximately $102,800. This firm-fixed price contract, which was completed on November 23, 2021, supports the VA's mission to provide specialized pharmaceutical treatments to veterans. The delivery order was issued under the Pharmaceuticals and Drugs Federal Supply Schedule...
- This is a closeout delivery order modification issued by the Department of Veterans Affairs Veterans Integrated Service Network 20 (VISN 20) to Otsuka America Pharmaceutical Inc. for a bulk purchase of Tolvaptan (Jynarque), a specialized pharmaceutical treatment for autosomal dominant polycystic kidney disease and hyponatremia. The contract, awarded on October 1, 2021, with a firm fixed price and ceiling value of $203,334.36, was completed by September 30, 2022. The delivery order was placed...